Aura Biosciences, Inc. AURA
Institutional shares held
51.5 Million
0
calls
0
puts
Total value of holdings
$307M
$0
calls
$0
puts
Market Cap
$175M
29,273,600
Shares Out.
Institutional ownership
175.92%
# of Institutions
105
We take great care to ensure that the data presented and summarized in this overview for Aura Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURA
View all-
Matrix Capital Management Company, LP Waltham, MA6.92MShares$41.3 Million22.54% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.1MShares$30.4 Million1.68% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.88MShares$29.1 Million0.05% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$27.6 Million1.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.37MShares$26.1 Million0.94% of portfolio
-
Medicxi Ventures Management (Jersey) LTD3.04MShares$18.1 Million5.39% of portfolio
-
Black Rock Inc. New York, NY3.01MShares$17.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.48MShares$14.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.34MShares$14 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.12MShares$12.6 Million0.58% of portfolio
Latest Institutional Activity in AURA
Top Purchases
Top Sells
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 18
2025
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
7,722
-8.19%
|
$46,332
$6.7 P/Share
|
|
Aug 18
2025
|
Amy Elazzouzi Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
12,899
+2.0%
|
$51,596
$4.48 P/Share
|
|
Jun 17
2025
|
Antony C. Mattessich |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+35.62%
|
-
|
|
Jun 17
2025
|
David Michael Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+6.76%
|
-
|
|
Jun 17
2025
|
Sapna Srivastava |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+35.62%
|
-
|
|
Jun 02
2025
|
Pinos Elisabet De Los |
SELL
Payment of exercise price or tax liability
|
Direct |
9,948
-2.02%
|
$59,688
$6.16 P/Share
|
|
Jun 02
2025
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
10,948
+2.17%
|
$54,740
$5.07 P/Share
|
|
Jun 02
2025
|
Anthony S Gibney |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+42.02%
|
-
|
|
May 16
2025
|
David Michael Johnson |
BUY
Open market or private purchase
|
Direct |
20,000
+10.74%
|
$80,000
$4.9 P/Share
|
|
May 16
2025
|
Anthony S Gibney |
SELL
Open market or private sale
|
Direct |
1,519
-2.6%
|
$7,595
$5.15 P/Share
|
|
May 16
2025
|
Anthony S Gibney |
BUY
Open market or private purchase
|
Direct |
50,000
+46.1%
|
$200,000
$4.9 P/Share
|
|
Apr 16
2025
|
Conor Kilroy |
SELL
Open market or private sale
|
Direct |
7,162
-3.84%
|
$35,810
$5.49 P/Share
|
|
Apr 16
2025
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
897
-1.09%
|
$4,485
$5.49 P/Share
|
|
Mar 31
2025
|
Teresa Marie Bitetti |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+50.0%
|
-
|
|
Feb 18
2025
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
20,221
-4.02%
|
$141,547
$7.75 P/Share
|
|
Feb 18
2025
|
Janet Jill Hopkins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,534
-0.93%
|
$17,738
$7.75 P/Share
|
|
Feb 18
2025
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,404
-1.68%
|
$9,828
$7.75 P/Share
|
|
Feb 18
2025
|
Mark Plavsic Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,151
-1.02%
|
$15,057
$7.75 P/Share
|
|
Feb 03
2025
|
Amy Elazzouzi Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
45,240
+35.09%
|
-
|
|
Feb 03
2025
|
Conor Kilroy |
BUY
Grant, award, or other acquisition
|
Direct |
90,475
+32.67%
|
-
|
Last 12 Months Summary
Buy / Acquisition
901K
Shares
From
15
Insiders
| Grant, award, or other acquisition | 751K shares |
|---|---|
| Open market or private purchase | 70K shares |
| Exercise of conversion of derivative security | 79.4K shares |
Sell / Disposition
150K
Shares
From
8
Insiders
| Open market or private sale | 140K shares |
|---|---|
| Payment of exercise price or tax liability | 9.95K shares |